Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study-Reference-Cited by-同舟云学术

Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

Published:2017-05-16 Issue:1 Volume:10 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Lee Ji Won,Lee Sanghoon,Cho Hee Won,Ma Youngeun,Yoo Keon Hee,Sung Ki Woong,Koo Hong Hoe,Cho Eun Joo,Lee Suk-Koo,Lim Do Hoon

Funder

National R & D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-017-0477-0.pdf

Reference39 articles.

1. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348–57.

2. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649–58.

3. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–73.

4. Philip T, Ladenstein R, Lasset C, Hartmann O, Zucker JM, Pinkerton R, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer. 1997;33:2130–5.

5. Ladenstein R, Potschger U, Pearson AD, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500–14.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response‐adapted consolidation therapy strategy for patients with metastatic high‐risk neuroblastoma: Results of the SMC NB‐2014 study;Pediatric Blood & Cancer;2024-07-04

2. Sarcopenia with decreased total psoas muscle area in children with high-risk neuroblastoma;Asian Journal of Surgery;2024-06

3. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma;EJC Paediatric Oncology;2024-06

4. Long-term effects of local radiotherapy on growth and vertebral features in children with high-risk neuroblastoma;BMC Pediatrics;2024-05-30

5. Tandem high-dose multiagent chemotherapy followed by autologous stem cell transplantation in children with high-risk neuroblastoma;Pediatric Hematology/Oncology and Immunopathology;2024-04-08